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Abstract
6-Phenyl-4H-furo[3,2-c]pyran-4-one derivatives based on neo-tashinlactone (1) were synthesized
and evaluated as novel anti-breast cancer agents. Compounds 10-13, 23, 25, and 27 showed potent
inhibition against the SK-BR-3 breast cancer cell line. Importantly, 25 and 27 showed the highest
cancer cell line selectivity, being approximately 100- to 250-fold more potent against SK-BR-3
(ED50 0.28 and 0.44 μM, respectively) compared with other cancer cell lines tested. In addition,
25 displayed low cytotoxicity against normal breast cell lines 184A1 and MCF10A. Compounds
25 and 27 merit further investigation in our continuing program to generate and develop selective
anti-breast cancer agents.
Introduction
Breast cancer is the most common cancer among women.1-3 According to the American Cancer
Society, the disease accounts for more than one quarter of cancers diagnosed in US women.
In 2007, it was estimated that 18,000 new cases of invasive breast cancer would be diagnosed
in women, as well as an estimated 60,000 additional cases of in situ breast cancer.4
Most clinically used anticancer drugs cause general toxicity to proliferating cells, which can
severely limit the therapeutic value of these drugs.5 Thus, much effort has been made to increase
© 2009 Elsevier Ltd. All rights reserved.
*To whom correspondence should be addressed. KHL. Phone: 919-962-0066. Fax: 919-966-3893. khlee@unc.edu; KFB. Phone:
919-966-7633. ken_bastow@unc.edu; QS. Phone: 919-843-6325. qshi1@email.unc.edu..
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting
proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could
affect the content, and all legal disclaimers that apply to the journal pertain.
Supporting Information Available: HPLC analysis for final compounds.
NIH Public Access
Author Manuscript
Bioorg Med Chem. Author manuscript; available in PMC 2011 January 15.
Published in final edited form as:













tissue, cell, and target selectivity for chemotherapy.6-8 However, although new cytotoxic
agents with unique mechanisms of action have been developed continuously, many of them
have not been therapeutically useful due to low tumor selectivity.5 These facts prompted us to
design and develop novel potent and selective anti-breast cancer agents.
Natural products have been the most important source of new medicinal leads. 9-11 However,
the structural complexity of natural products, such as intricate ring systems and numerous chiral
centers, may lead to limited supplies and hamper mechanism of action studies and clinical
development.12 For this reason, structural simplification of natural products is a powerful and
highly productive tool for lead development and analog design.13 A well-known example is
the simplification of morphine, which led to the clinically used medicines levophanol and
meperidine.14 Neo-tanshinlactone (1) is a steroid-like tetracyclic natural product originally
isolated from the traditional Chinese medicine Tanshen. Compound 1 and its first generation
analog 2 with various substituents around the molecular scaffold were totally synthesized and
previously studied for biological activity. Compound 1 was reported as a highly selective
inhibitor of the growth of breast cancer cell lines SK-BR-3 (HER2 over-expressing breast
cancer) and ZR-75-1 (estrogen receptor positive breast cancer).2, 15 Although previous studies
provided much information about the structure-activity relationships, several questions
remained unanswered: how does the skeletal planarity affect activity and selectivity, how do
each of the four individual rings contribute to activity, and how will the activity and selectivity
change by simplification of the tetracyclic molecule of 1. We used chemical and biological
strategies to investigate structurally simplified 1-analogs to answer these questions.
In our prior paper, we reported a study on how the individual A, C, and D rings influence in
vitro anti-breast cancer activity.16 The results revealed that 2-(furan-2-yl)-naphthalen-1-ol
derivatives (e.g., 3), in which ring-C of 1 is missing, are a new class of potent and selective
anti-breast cancer agents. These results encouraged us to further simplify the scaffold of 1.
Herein, we report a new chemical entity, substituted 6-phenyl-4H-furo[3,2-c]pyran-4-one
derivatives (4), the synthesis of these 4-analogs, and their cytotoxic activity against a human
tumor cell line panel.
Chemistry
All target compounds 9-30 were synthesized through a three to five-step sequence (Scheme
1). Various substituted esters 5 were reacted with a dianion intermediate generated from ethyl
acetoacetate with LDA and TMEDA to give triketoesters 6 as tautomeric mixtures. Pyrones
7 were prepared by heating 6 in a 170 °C oil bath under reduced pressure. The resulting yellow
solid was isolated by vacuum filtration, and the compound used directly in the next step.17
Target compounds 9-11, 14-17, 19, 21-22, 24-25, and 27-29 were obtained via a tandem
alkylation/intramolecular Aldol reaction of 7.18 Removal of the methyl group in 11, 17, 19,
22, and 25 by BBr3 gave 13, 18, 20, 23, and 26. Compound 12 was obtained by treatment of
13 with iodoethane under basic conditions (Scheme 1). Compound 25 was reacted with
Lawesson's reagent to afford 30.19
Results and Discussion
Together with 1, the newly synthesized 6-phenyl-4H-furo[3,2-c]pyran-4-one analogs 9–30
were evaluated for in vitro anti-breast cancer activity against the SK-BR-3 human tumor cell
line. Results from 9–27 (Table 1) showed that different substituents around the phenyl ring
were critical to the potency and selectivity. Modifications in the furopyranone ring system were
also explored with 28–30 (Table 1). Selected active compounds with ED50 values less than 10
μM against SK-BR-3 were further examined against ZR-7-51, MDA-MB-231 (estrogen
receptor negative breast cancer), A549 (human lung cancer), DU145 (prostate cancer), KB
Dong et al. Page 2













(nasopharyngeal carcinoma), and KB-vin (vincristine resistant KB subline) cancer cell lines
(Table 2).
Structurally, both 1 and 10 have a methyl substituent at corresponding positions on their phenyl
rings. Thus, the two compounds are identical, except that 10 has no ring-B. Interestingly, 10
showed potent activity with an ED50 value of 1.50 μM, which is slightly less active than 1.
The unsubstituted analog 9 was less potent than either 1 or 10. Addition of methyl (10), methoxy
(11), ethoxy (12), and hydroxyl (13) at the R2-position of the phenyl ring increased activity
against the SK-BR-3 cell line, compared with 9. The rank order of potency of the five
compounds was 12 > 13 > 11 > 10 > 9. Compound 12, with a R2-ethoxyphenyl ring, displayed
slightly greater activity (ED50 0.67 μM) than 1. In contrast, fluorine at the R2-position (14), as
well as R3-position (15), led to somewhat decreased potency compared with the unsubstituted
analog 9. Addition of methyl, methoxy, or hydroxyl at the phenyl R3-position (16-18) reduced
potency significantly. Compounds 19-26 and 27 are di- and tri-substituted derivatives,
respectively, with one substituent always present at the phenyl R2-position. Neither R1, R2-
disubstituted compound (19, 20) showed significant activity, leading us to speculate that a
substituent in the R1-position may have a steric effect on the orientation of the lactone ring and
reduce the ligand-receptor interaction. Analogs with the same substituent at both the R2- and
R3-positions showed increased potency relative to the corresponding R3-monosubstituted
analog (16 vs 21, 17 vs 22, 18 vs 23). Thus, alkyl, alkoxy, and hydroxy groups are favored at
R2-position, while they are not favored at the R3-position. Comparison of 25 with 24 and 26
indicated that a methoxy group is favored at R4-position, while methyl and hydroxy groups
are not. Furthermore, the R2, R3, R4-trimethoxy (27) and R2, R4-dimethoxy (25) analogs
showed dramatically enhanced potency compared with the 3’-methoxy compound (11), while
the R2, R3-dimethoxy (22) and R1, R2-dimethoxy (19) analogs showed decreased potency. In
fact, the R2, R4-dimethoxy analog 25 (ED50 0.28 μM) was the most active analog among the
19 substituted phenyl A-ring analogs (9–27). It was also approximately threefold more potent
than 1.
We also investigated the cytotoxic activity of 28-30, which have a modified ring-C or -D, as
shown in Table 1. Insertion of an ethyl (28) or two methyl (29) groups rather than a single
methyl group on the furan, as well as bioisosteric replacement of sulfur (thiolactone 30) for
oxygen in the lactone carbonyl led to greatly reduced or no anti-breast cancer activity (Table
1). More SAR studies of ring-C and –D are in progress and will be reported in a future
publication.
To examine the human tumor-tissue-type selectivity, active compounds 10-13, 23, 25, and
27 were tested against a limited but diverse panel of human cancer cell lines, using 1 as a
positive control (Table 2). Compounds 10-13 and 23 displayed similar inhibition of the
ZR-75-1 and SKBR-3 cell lines. Interestingly, 25 and 27 showed very weak activity against
ZR-75-1. Except for 23, all lead compounds had weak activity or no activity against MDA-
MB-231 breast cancer or the remaining four cancer cell lines tested, which suggested high
tumor-tissue-type selectivity. Furthermore, 23 showed only moderate inhibition. Importantly,
25 and 27 showed unique selectivity against the SK-BR-3 breast cancer cell line (HER2+),
with approximately 100-250 fold differences compared with the other cancer cell lines tested.
The unique selectivity of these novel lead compounds could be exploited to develop novel anti-
breast cancer trials candidates and explore the mechanism(s) of action.
Compound 25 was tested independently against cell lines derived from normal breast tissue
(MCF10A and 184A1) versus SK-BR-3 as a positive breast cancer cell line control, and results
are shown in Figure 2. The interpolated ED50 values were 1.0, 16.8 and >35.0 μM against SK-
BR-3, 184A1, and MCF10A cells, respectively, showing that 25 is selective for a sub-set of
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breast cancer-derived cell lines and is significantly less active against normal breast-derived
tissue.
Conclusions
In conclusion, this study discovered a novel class of promising anti-breast cancer agents,
substituted 6-phenyl-4H-furo[3,2-c]pyran-4-one derivatives. The ED50 values of the two most
potent analogs (25 and 27) against SK-BR-3 were 0.28 and 0.44 μM, respectively. More
importantly, 25 and 27 showed extremely high cancer cell line selectivity, being approximately
100- to 250-fold more potent against SK-BR-3 compared with six additional tested cancer cell
lines. Furthermore, 25 displayed much greater potency against the SK-BR-3 breast cancer cell
line compared with normal breast cell lines 184A1 and MCF10A. Preliminary SAR studies
led to the following observations. (1) R2-Methyl, methoxy, ethoxy, and hydroxy groups, but
not a R2-fluoro group, could increase potency. (2) Among disubstituted phenyl compounds,
R1-, R3-, or R4-methyl groups, R1- or R3-methoxy groups, and R4-hydroxy groups decreased
potency; while a R3-hydroxy or R4-methoxy group increased potency. (3) Current
modifications in ring-C and -D were not preferred. The SAR profile established from the
current study is different from that with the neo-tanshinlactone series, which is a four-ring
system. Thus, skeletal planarity is not indispensable for the entire molecule, though it may be
important to some extent. Focused studies will continue to develop promising novel analogs
as clinical trials candidates for anti-breast cancer treatment.
Experimental Section
Materials and Methods
Melting points were measured with a Fisher Johns melting apparatus without correction. 1H
NMR spectra were measured on a 300 MHz Varian Gemini 2000 spectrometer using TMS as
internal standard. The solvent used was CDCl3 unless indicated. Mass spectra were measured
on a Shimadzu LC-MS2010 instrument. Thin-layer chromatography (TLC) and preparative
TLC were performed on precoated silica gel GF plates purchased from Merck, Inc. Biotage
Flash+ or Isco Companion systems were used for flash chromatography. Silica gel (200-400
mesh) from Aldrich, Inc. was used for column chromatography. All other chemicals were
obtained from Aldrich, Inc. and Fisher, Inc. Preparation of intermediates 6 and 7 were reported
by Douglas, etc.17
Cell Growth Inhibition Assay
All stock cultures are grown in T-25 flasks. Freshly trypsinized cell suspensions were seeded
in 96-well microtiter plates with compounds added from DMSO-diluted stock. The plates were
incubated for an additional 72 h after attachment and drug addition, and the assay was
terminated by 10% TCA. Then, 0.4% SRB dye in 1% HOAc was added to stain the cells for
10 minutes. Unbound dye was removed by repeated washing with 1% HOAc and the plates
were air dried. Bound stain was subsequently solved with 10 mM trizma base, and the
absorbance read at 515 nm. Growth inhibition of 50% (ED50) is calculated as the drug
concentration, which caused a 50% reduction in the net protein increase during the drug
incubation. The mean ED50 is the concentration of agent that reduces cell growth by 50% under
the experimental conditions and is the average with SEM from at least two independent
determinations. Variation between replicates was no more than 5% of the mean. The following
human tumor cell lines were used in the assay: A549 (non small cell lung cancer, ZR-75-1
(estrogen receptor positive breast cancer), MDA MB-231 (estrogen receptor negative breast
cancer), SK-BR-3 (HER2 over-expressing breast cancer), KB (nasopharyngeal carcinoma),
KB-VIN (vincristine-resistant KB subline). All cell lines were obtained from the Lineberger
Cancer Center (UNC-CH) or from ATCC (Rockville, MD). Cells propagated in RPMI-1640
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supplemented with 10% FBS, penicillin (100 IU/mL), streptomycin (1 μg/mL), and
amphotericin B (0.25 μg/mL), and were cultured at 37 °C in a humidified atmosphere of 95%
air/5% CO2.
General preparation of 9-11, 14-17, 19, 21-22, 24-25, 27-29—To a solution of 7 (1.04
mmol) in toluene (9 mL) was added a mixture of HOAc (0.30 ml, 5.20 mmol) and NH4OAc
(400 mg, 5.20 mmol) in EtOH (3 mL) and chloroacetone (0.42 mL, 5.20 mmol). The mixture
was stirred for 30 min at rt, and then heated to 60 °C for 30 min. Subsequently, it was refluxed
for 24 h. After cooling, the mixture was diluted with H2O and extracted with EtOAc. The
organic layer was dried over Na2SO4, filtered, and evaporated in vacuo. The residue was
purified by column chromatography to give a solid.
3-Methyl-6-phenyl-4 H-furo[3,2-c]pyran-4-one (9)—50% yield; mp 105-107 °C; 1H
NMR (300 MHz, CDCl3, ppm): δ 2.33 (d, J = 1.2 Hz, 3H, CH3), 7.00 (s, 1H, OCH), 7.28-7.29
(m, 1H, C7-H), 7.43-7.46 (m, 3H, aromatic), 7.83-7.87 (m, 2H, aromatic); HRMS for (M++H):
calcd. 227.0708, found: 227.0696.
3-Methyl-6-m-tolyl-4H-furo[3,2-c]pyran-4-one (10)—52% yield; mp 135-137 °C; 1H
NMR (300 MHz, CDCl3, ppm): δ 2.33 (d, J = 1.2 Hz, 3H, CH3), 2.42 (s, 3H, CH3), 6.99 (s,
1H, C7-H), 7.23-7.36 (m, 3H, aromatic), 7.62 (d, J = 7.2 Hz, 1H, aromatic), 7.69 (d, J = 1.5
Hz, 1H, OCH); HRMS for (M++H): calcd. 241.0865, found: 241.0851.
6-(3-Methoxyphenyl)-3-methyl-4H-furo[3,2-c]pyran-4-one (11)—44% yield; mp
119-121 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.34 (d, J = 1.5 Hz, 3H, CH3), 3.87 (s, 3H,
OCH3), 6.96-7.00 (m, 2H), 7.29-7.44 (m, 4H); 13 C NMR (300 MHz, CDCl3, ppm): δ 8.52,
55.47, 93.64, 109.91, 110.68, 116.36, 117.82, 119.55, 129.91, 133.07, 140.76, 157.71, 159.39,
160.01, 161.93; HRMS for (M++H): calcd. 257.0814, found: 257.0800.
6-(3-Fluorophenyl)-3-methyl-4H-furo[3,2-c]pyran-4-one (14)—34%yield; mp
158-160 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.34 (d, J = 1.5 Hz, 3H, CH3), 7.01 (s, 1H,
C7-H), 7.10-7.17 (m, 1H, aromatic), 7.31 (d, J = 1.2 Hz, 1H, OCH), 7.39-7.46 (m, 1H,
aromatic), 7.54-7.58 (m, 1H, aromatic), 7.61-7.65 (m, 1H, aromatic); HRMS for (M++H):
calcd. 245.0614, found: 245.0603.
6-(4-Fluorophenyl)-3-methyl-4H-furo[3,2-c]pyran-4-one (15)—52% yield; mp
175-177 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.34 (d, J = 1.5 Hz, 3H, CH3), 6.94 (s, 1H,
C7-H), 7.12-7.18 (m, 2H, aromatic), 7.29 (d, J = 1.2 Hz, 1H, OCH), 7.82-7.87 (m, 2H,
aromatic); HRMS for (M++H): calcd. 245.0614, found: 245.0603.
3-Methyl-6-p-tolyl-4H-furo[3,2-c]pyran-4-one (16)—62% yield; mp 153-155 °C; 1H
NMR (300 MHz, CDCl3, ppm): δ 2.33 (d, J = 1.2 Hz, 3H, CH3), 2.40 (s, 3H, CH3), 6.95 (s,
1H, C7-H), 7.24-7.27 (m, 3H, aromatic & OCH), 7.74 (d, J = 8.1 Hz, 2H, aromatic); HRMS
for ([M+H]+): calcd. 241.0865, found: 241.0848.
6-(4-Methoxyphenyl)-3-methyl-4H-furo[3,2-c]pyran-4-one (17)—60% yield; mp
146-148 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.33 (d, J = 1.5 Hz, 3H, CH3), 3.87 (s, 3H,
OCH3), 6.88 (s, 1H, C7-H), 6.97 (d, J = 9.0 Hz, 2H, aromatic), 7.26 (d, J = 1.5 Hz, 1H,
OCH), 7.80 (d, J = 9.0 Hz, 2H, aromatic); HRMS for ([M+H]+): calcd. 257.0808, found:
257.0816.
6-(2,3-Dimethoxyphenyl)-3-methyl-4H-furo[3,2-c]pyran-4-one (19)—40% yield;
mp 111-113 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.34 (d, J = 1.2 Hz, 3H, CH3), 3.87 (s,
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3H, OCH3), 3.92 (s, 3H, OCH3), 7.00 (dd, J = 1.2, 8.1 Hz, 1H, aromatic), 7.16 (t, J = 8.1 Hz,
1H, aromatic), 7.34 (q, J = 1.2 Hz, 1H, OCH), 7.48 (s, 1H, C7-H), 7.54 (dd, J = 1.2, 8.1 Hz,
1H, aromatic); HRMS for (M++H): calcd. 287.0919, found: 287.0906.
6-(3,4-Dimethylphenyl)-3-methyl-4H-furo[3,2-c]pyran-4-one (21)—67% yield; mp
182-184 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.30 (s, 3H, CH3) 2.32 (s, 3H, CH3), 2.33
(d, J = 1.5 Hz, 3H, CH3), 6.95 (s, 1H, C7-H), 7.20 (d, J = 8.1 Hz, 1H, aromatic), 7.26 (d, J =
1.2 Hz, 1H, OCH), 7.57 (d, J = 8.1 Hz, 1H, aromatic), 7.64 (s, 1H, aromatic); HRMS for ([M
+H]+): calcd. 255.1016, found: 255.1010.
6-(3,4-Dimethoxyphenyl)-3-methyl-4H-furo[3,2-c]pyran-4-one (22)—83% yield;
mp 154-156 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.33 (d, J = 1.5 Hz, 3H, CH3), 3.94 (s,
3H, OCH3), 3.98 (s, 3H, OCH3), 6.90 (s, 1H, C7-H), 6.92 (d, J = 8.7 Hz, 1H, aromatic), 7.27
(t, J = 1.5 Hz, 1H, OCH), 7.34 (d, J = 2.1 Hz, 1H, aromatic), 7.43 (dd, J = 2.1, 8.4 Hz, 1H,
aromatic); HRMS for (M++H): calcd. 287.0919, found: 287.0900.
6-(3,5-Dimethylphenyl)-3-methyl-4H-furo[3,2-c]pyran-4-one (24)—30% yield; mp
171-173 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.33 (d, J = 0.9 Hz, 3H, CH3), 2.37 (s, 6H,
CH3), 6.98 (s, 1H, C7-H), 7.07 (s, 1H, aromatic), 7.28 (d, J = 0.9 Hz, 1H, OCH), 7.48 (s, 2H,
aromatic); HRMS for (M++H): calcd. 255.1021, found: 255.1010.
6-(3,5-Dimethoxyphenyl)-3-methyl-4H-furo[3,2-c]pyran-4-one (25)—38%, yield;
mp 153-155 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.34 (d, J = 1.5 Hz, 3H, CH3), 3.86 (s,
6H, OCH3), 6.54 (t, J = 2.1 Hz, 1H, C7-H), 6.98 (s, 1H, aromatic), 6.99 (d, J = 2.7 Hz, 2H,
aromatic), 7.30 (d, J = 1.5 Hz, 1H, OCH); HRMS for (M++H): calcd. 287.0919, found:
287.0898.
3-Methyl-6-(3,4,5-trimethoxyphenyl)-4H-furo[3,2-c]pyran-4-one (27)—40% yield;
mp 201-203 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.34 (d, J = 1.5 Hz, 3H, CH3), 3.91 (s,
3H, OCH3), 3.95 (s, 6H, OCH3), 6.94 (s, 1H, C7-H), 7.06 (s, 2H, aromatic), 7.29 (d, J = 1.2
Hz, 1H, OCH); HRMS for (M++H): calcd. 317.1025, found: 317.1037.
6-(3,5-Dimethoxyphenyl)-3-ethyl-4H-furo[3,2-c]pyran-4-one (28)—51% yield; mp
131-133 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 1.31 (t, J = 7.2 Hz, 3H, CH2CH3), 2.77 (q,
J = 7.5 Hz, 2H, CH2CH3), 3.86 (s, 6H, OCH3), 6.54 (t, J = 2.1 Hz, 1H, C7-H), 6.98 (d, J = 2.1
Hz, 3H, aromatic), 7.30 (t, J = 1.2 Hz, 1H, OCH); HRMS for (M++H): calcd. 301.1076, found:
301.1057.
6-(3,5-Dimethoxyphenyl)-2,3-dimethyl-4H-furo[3,2-c]pyran-4-one (29)—12%
yield; mp 163-165 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.25 (d, J = 0.6 Hz, 3H, CH3),
2.33 (d, J = 0.6 Hz, 3H, CH3), 3.86 (s, 6H, OCH3), 6.53 (t, J = 2.1 Hz, 1H, aromatic), 6.93 (s,
1H, OCH), 6.97 (d, J = 2.1 Hz, 2H, aromatic); HRMS for ([M+H]+): calcd. 301.1071, found:
301.1067.
General preparation of 13, 20, 23, and 26—To a solution of 13, 20, 23, or 26 (0.2 mmol)
in DCM (3 ml) was added BBr3 (0.6 ml, 0.6 mmol) dropwise at 0 °C. The reaction mixture
was stirred overnight. Water was added to quench the reaction. The solution was extracted with
CHCl3 and concentrated. The residue was purified by column chromatography to give a white
solid.
6-(3-Hydroxyphenyl)-3-methyl-4H-furo[3,2-c]pyran-4-one (13)—78% yield; mp
225-227 °C; 1H NMR (300 MHz, CD3OD, ppm): δ 2.29 (d, J = 1.5 Hz, 3H, CH3), 6.86-6.90
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(m, 1H, C7-H), 7.26-7.31 (m, 3H, aromatic & OCH), 7.35-7.39 (m, 1H, aromatic), 7.52 (dd,
J = 1.2, 2.7 Hz, 1H, aromatic); HRMS for (M++H): calcd. 243.0657, found: 243.0659.
6-(4-Hydroxyphenyl)-3-methyl-4H-furo[3,2-c]pyran-4-one (18)—80% yield; mp
258-260 °C; 1H NMR (300 MHz, CD3OD, ppm): δ 2.27 (d, J = 1.5 Hz, 3H, CH3), 6.86 (d, J
= 9.0 Hz, 2H, aromatic) 7.18 (s, 1H, C7-H), 7.46 (d, J = 1.2 Hz, 1H, OCH), 7.75 (d, J = 9.3
Hz, 2H, aromatic); HRMS for ([M+H]+): calcd. 243.0657, found: 243.0641.
6-(2,3-Dihydroxyphenyl)-3-methyl-4H-furo[3,2-c]pyran-4-one (20)—66% yield; mp
239-241 °C; 1H NMR (300 MHz, CD3OD, ppm): δ 2.28 (d, J = 0.9 Hz, 3H, CH3), 6.76 (t, J =
1.5 Hz, 1H, aromatic), 6.86 (dd, J = 1.5, 1.8 Hz, 1H, aromatic), 7.38 (dd, J = 1.2, 1.5 Hz, 1H,
aromatic), 7.48 (q, J = 1.2 Hz, 1H, OCH), 7.75 (s, 1H, C7-H); HRMS for (M++H): calcd.
259.0606, found: 259.0602.
6-(3,4-Dihydroxyphenyl)-3-methyl-4H-furo[3,2-c]pyran-4-one (23)—60% yield; mp
259-261 °C; 1H NMR (300 MHz, CD3OD, ppm): δ 2.69 (d, J = 1.5 Hz, 3H, CH3), 6.83 (d, J
= 7.8 Hz, 3H, C7-H), 7.12 (s, 1H, aromatic), 7.26-7.31 (m, 2H, aromatic), 7.46 (dd, J = 1.2 Hz,
1H, OCH); HRMS for (M+-H): calcd. 257.0450, found: 257.0464.
6-(3,5-Dihydroxyphenyl)-3-methyl-4H-furo[3,2-c]pyran-4-one (26)—70% yield; mp
>300 °C; 1H NMR (300 MHz, CD3OD, ppm): δ 2.86 (d, J = 1.2 Hz, 3H, CH3), 6.35 (t, J = 2.1
Hz, 1H, aromatic), 6.80 (d, J = 2.1 Hz, 2H, aromatic), 7.21 (s, 1H, C7-H), 7.51 (d, J = 1.2 Hz,
1H, OCH); HRMS for ([M+H]+): calcd. 259.0601, found: 259.0594.
6-(3-Ethoxyphenyl)-3-methyl-4H-furo[3,2-c]pyran-4-one (12)—To a mixture of 13
(212 mg, 1.00 mmol), K2CO3 (300 mg, 2.17 mmol) in actone (8 mL) was added iodoethane
(0.4 mL, 5.00 mmol). The mixture was stirred for 12 h. The mixture was concentrated and
diluted with H2O and extracted with EtOAc. The organic layer was dried over Na2SO4, filtered,
and evaporated. The residue was purified by column chromatography to give a white solid.
35% yield; mp 128-130 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 1.45 (t, J = 6.9 Hz, 3H,
CH2CH3), 2.33 (d, J = 1.5 Hz, 3H, CH3), 4.10 (d, J = 7.2 Hz, 2H, CH2CH3), 6.95-6.96 (m,
1H, aromatic), 6.98 (s, 1H, C7-H), 7.29 (d, J = 1.5 Hz, 1H, OCH), 7.32-7.43 (m, 3H, aromatic);
HRMS for ([M+H]+): calcd. 271.0965, found: 271.0962.
6-(3,5-Dimethoxyphenyl)-3-methyl-4H-furo[3,2-c]pyran-4-thione (30)—A mixture
of 25 (0.1 mmol) and Lawesson's reagent (81 mg, 0.2 mmol) in dry toluene (5 mL) was heated
to reflux for 12 h. Toluene was removed and the red residue was dissolved in EtOAc and
partitioned with H2O. The organic phase was separated and dried over Na2SO4. Removal of
solvent in vacuo afforded an oily, residue which was purified by column chromatography
resulting in a yellow solid.
60% yield; mp 147-149 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.46 (d, J = 1.5 Hz, 3H,
CH3), 3.87 (s, 6H, OCH3), 6.57 (t, J = 2.1 Hz, 1H, C7-H), 7.02 (s, 1H, aromatic), 7.03 (s, 1H,
aromatic), 7.17 (s, 1H, aromatic), 7.32 (d, J = 1.5 Hz, 1H, OCH); HRMS for (M++H): calcd.
303.0691, found: 303.0702.
Methodology of MTT assay
The MTT assay was used to independently test the potent activity of 25 against SK-BR-3 and
to investigate antitumor selectivity versus activity against two normal breast cancer cell lines:
184A1 and MCF10A (CRL-10317) purchased from ATCC (Rockville, MD). Cells were seeded
into 96 well plates at a density of 5000 cells per well in the recommended growth medium.
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The drug was dissolved in DMSO. The drug was added into wells after overnight incubation.
After 72 h of incubation at 37 °C in 5% CO2, 20 μL of MTT [3-(4,5-dimethylthiazol-2-yl)-2,5
-diphenyl tetrazolium bromide] reagent was added to each well and incubation continued for
2 h. The amount of formazan product was measured at an OD of 570 nM using a plate-reader.
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Structures of neo-tanshinlactone (1), a first generation neo-tanshinlactone analog 2, a second
generation optimized analog 3, and a newly designed scaffold 4
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Selective in vitro anticancer activity of 25 against SK-BR-3 breast cancer versus normal breast
tissue-derived cell lines (MCF10A and 184A1). Legend: Cell line description, source and
activity determination using the MTT-dye assay are described in the experimental section.
Graphical data are the mean and standard deviation of values obtained from replicates in a
single experiment.
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